Wellington Biomedical Innovation Master Investors (Cayman) II L.P.
CIK: 0001903360
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MBX Biosciences to Attend Investor Conferences, Analyst Target Raised. MBX Biosciences will join several investor conferences in November, offering a chance for investors to hear about its pipeline. Stifel has kept a positive stance and lifted its target price to $84. Analysts are debating whether the recent 257% jump has pushed the stock above fair value, while others question if the pullback from a strong year run still leaves room for upside.
Transaction History
| AVLN | ▼ Sell | Other | 1,275,486 | — | 5/1/2026 | View on chart |
| UPB | ▼ Sell | Other | 894,733 | — | 10/15/2024 | View on chart |
| MBX | ▼ Sell | Other | 1,386,335 | — | 9/16/2024 | View on chart |
| MBX | ▼ Sell | Other | 403,787 | — | 9/16/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
AVLN releases Phase 1 data for AP02 inhaled therapy
Avalyn Pharma released Phase 1 results for its inhaled antifibrotic candidate AP02. The trials in healthy volunteers and patients with idiopathic pulmonary fibrosis showed lung‑targeted delivery and an encouraging safety profile. The publication follows recent discussion of the company's valuation and adds clinical evidence supporting the inhaled approach.
AVLN releases Phase 1 data for AP02 inhaled therapy. Avalyn Pharma released Phase 1 results for its inhaled antifibrotic candidate AP02. The trials in healthy volunteers and patients with idiopathic pulmonary fibrosis showed lung‑targeted delivery and an encouraging safety profile. The publication follows recent discussion of the company's valuation and adds clinical evidence supporting the inhaled approach.